NAD supplementation dosage in clinical trials
Pro Research Analysisby 
Searched over 200M research papers
NAD Supplementation Dosage in Clinical Trials: Key Findings
NMN Supplementation Dosage and Effects in Clinical Trials
Clinical trials have tested a range of nicotinamide mononucleotide (NMN) dosages, typically from 150 mg to 1250 mg per day, to assess their impact on NAD levels and health outcomes in adults. Studies consistently show that NMN supplementation increases blood NAD concentrations in a dose-dependent manner, with higher doses (600 mg and 900 mg daily) leading to the greatest increases in NAD levels and improvements in physical performance, such as walking distance in the six-minute walk test. Doses up to 900 mg daily were well tolerated over 60 days, with no significant safety concerns reported. The highest tested dose, 1250 mg daily for four weeks, was also found to be safe and well tolerated in healthy adults, with no severe adverse events observed 1258910.
Interindividual Variability and Personalized Dosage
There is significant variability in how individuals respond to NMN supplementation, with changes in NAD levels varying widely between participants. This suggests that monitoring NAD concentrations could help tailor personalized NMN dosage regimens for optimal benefit, rather than relying on a one-size-fits-all approach .
NMN Dosage in Special Populations and Long-Term Use
Long-term NMN supplementation at 250 mg per day for 12 weeks was shown to be safe and effective in increasing NAD metabolism in healthy middle-aged adults, with no adverse events reported. Additionally, a systematic review of randomized controlled trials found that NMN dosages ranging from 150 mg to 1200 mg per day were generally well tolerated, with no serious adverse effects linked to supplementation 910.
Nicotinamide Riboside (NR) Supplementation Dosage
Nicotinamide riboside (NR), another NAD precursor, has been tested in clinical trials at doses from 100 mg to 2000 mg per day. Studies show that NR supplementation increases NAD+ levels in a dose-dependent manner, with a 40% increase at recommended doses and up to a 90% increase at double doses over eight weeks. High-dose NR (up to 3000 mg per day) was also found to be safe and well tolerated in a four-week trial in individuals with Parkinson’s disease, with no moderate or severe adverse events reported 367.
Nicotinamide Supplementation Dosage
Single-dose supplementation of nicotinamide (vitamin B3) at 200 mg, which is within the daily tolerable upper level, led to a significant but transient increase in blood NAD+ levels in healthy subjects. These findings support further evaluation of repeated dosing within the safety range for potential benefits .
Conclusion
Clinical trials indicate that NMN supplementation is safe and well tolerated at doses up to 1250 mg per day for up to 4–12 weeks, with the most pronounced increases in NAD levels and physical performance seen at 600–900 mg daily. NR supplementation is also safe at doses up to 2000–3000 mg per day, with significant increases in NAD+ levels. There is considerable individual variability in response, highlighting the potential value of personalized dosing based on NAD monitoring. Overall, NAD precursor supplementation appears safe across a range of dosages, with no serious adverse effects reported in healthy adults.
Sources and full results
Most relevant research papers on this topic